We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 18, 2020

Afatinib Plus Cetuximab vs Afatinib Alone for First-Line Treatment of EGFR-Mutant NSCLC

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
J. Clin. Oncol 2020 Oct 06;[EPub Ahead of Print], SB Goldberg, MW Redman, R Lilenbaum, K Politi, TE Stinchcombe, L Horn, EH Chen, SH Mashru, SN Gettinger, MA Melnick, RS Herbst, MA Baumgart, J Miao, J Moon, K Kelly, DR Gandara

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading